ClinicalTrials.gg
Not yet recruitingNCT05503979EHCUSUpdated Nov 6, 2026

Elimination of Hepatitis C Virus Among Users of Substances

An observational study in Hepatitis C in Substance Users, sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Observational

How we know

Updated Nov 6, 2026Now Not yet recruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

Substance users are a vulnerable group that should be prioritized in HCV (Hepatitis C Virus) elimination efforts in Mexico and in which it is feasible to carry out micro-elimination programs. It is an important group to treat both because of its high prevalence and because of the dynamic spread of infection among the general population. HCV seropositivity has not been documented in this group of people in Mexico City, the metropolitan area and the northern states of the country, nor has the sustained viral response been evaluated in this group of patients in the Mexican population.

Read the detailed description

The investigators would use a work team, the program and the value proposal would be presented to the local authorities, the coordinator of the national commission against dependencies and doctors. The investigators would use an algorithm designed for the first-step diagnosis of HCV in SUs (Substances Users) , and defined the key centers for screening and linking to care.

The project is planned as follows:

  • Screening: SUs in centers of substance users in Mexico City, the metropolitan area and states in the North of the country will be evaluated with rapid tests. Those with a positive result will be selected.
  • Diagnosis: Patients with a positive rapid test result will undergo a viral load test against HCV. Those with positive results will be selected.
  • Link-up: Those who are confirmed positive will be profiled to receive treatment at INCMNSZ. they will receive damage reduction to prevent reinfection or primary infection in negatives (granted by the rehabilitation center).
  • Treatment: The treatment will be received in a certified hospital (INCMNSZ) to treat patients with HCV infection, the treatment will be indicated by doctors who work in this hospital in the treatment consultations for hepatitis C or in centers with substance users with doctors trained to administer the treatment. This training will be received by telementoring. And also during the treatment, follow-up will be given with telementoring sessions if necessary. This group of people has personality characteristics that require a integral treatment, so it will be a integral and multidisciplinary treatment with psychological care and harm reduction (provided by the rehabilitation center)
  • Confirm SVR: A viral load test will be performed 12 weeks after the end of treatment to corroborate SVR. They will be given after this a mentorship for harm reduction and advice against reinfections

The importance of this project is characterized by minimal monitoring, patients and doctors education by telementoring, multidisciplinary teams and integral treatment

02

Conditions studied

  • Hepatitis C in Substance Users

Browse trials for

Keywords

  • HCV
  • Elimination
  • Substance Users
03

In context

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 218 across 435 observational studies indexed under Hepatitis C.

Browse Hepatitis C studies →

Lead sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran is the lead sponsor of 145 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Substances Users who are registered in the rehabilitation centers that comply with the applicable regulations in Mexico City, the metropolitan area and the northern states of the country.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years.
  • Active infection by virus.
  • People who use substances and who are users of rehabilitation centers in Mexico City, the metropolitan area and the northern states of the country.
  • Signature of

Exclusion criteria

Exclusion Criteria:

  • all those who do not fit the inclusion criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Substances Users

    Substances users confirmed with Viral Load for HCV. after that will be evaluated through laboratory studies (CBC and blood chemistry), HIV/HBV (Hepatitis B Virus) serology, fibrosis status will be evaluated through APRI (AST to Platelet Ratio Index) and FIB-4. The antiviral treatment (sofosbuvir/Velpatasvir) will be chosen according to the characteristics of each patient and follow-up will be maintained according to the national plan with a visit at the end of treatment and 12 weeks after its end to assess SVR. The importance of this project is characterized by minimal monitoring, patients and doctors education by telementoring, multidisciplinary teams and integral treatment.

    Drug: Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]

Interventions

  • DrugSofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]

    1 tab every 24 hrs for 12 weeks

    Also known as: Epclusa

06

What researchers measure

Primary outcomes

  1. Sustained viral response (SVR) in people who use substances in the Mexico City metropolitan area and the northern states of the country.

    Number por participants who achive SVR whit the treatment

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Seroprevalence and prevalence of HCV in people who use substances in the Mexico City metropolitan area and the northern states of the country.

    Number of participants with chronic HCV infection

    Time frame: through study completion, an average of 1 year

  2. No Sustained viral response (SVR) in people who use Substances in the Mexico City

    Number of participants who does not achive RVS

    Time frame: through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014. PubMed 24988388 ↗
  • Mendizabal M, Alonso C, Silva MO. Overcoming barriers to hepatitis C elimination. Frontline Gastroenterol. 2019 Jul;10(3):207-209. doi: 10.1136/flgastro-2018-101114. Epub 2019 Feb 1. No abstract available. PubMed 31288259 ↗
  • Lazarus JV, Safreed-Harmon K, Thursz MR, Dillon JF, El-Sayed MH, Elsharkawy AM, Hatzakis A, Jadoul M, Prestileo T, Razavi H, Rockstroh JK, Wiktor SZ, Colombo M. The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Semin Liver Dis. 2018 Aug;38(3):181-192. doi: 10.1055/s-0038-1666841. Epub 2018 Jul 9. PubMed 29986353 ↗
  • Wansom T, Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moore RD, Thomas DL, Sulkowski MS. Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infect Dis. 2017 Feb 11;4(1):ofx024. doi: 10.1093/ofid/ofx024. eCollection 2017 Winter. PubMed 28480293 ↗
  • Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014 Dec;12(12):1500-24. doi: 10.1016/j.ijsu.2014.07.014. Epub 2014 Jul 18. PubMed 25046751 ↗

Individual participant data

Plan to share: Yes — all IPD that underlie results in a publication would be shared

Supporting information: Clinical study report

Time frame: By 2024, once the enrollment of patients and the analyzes have been completed, this publication will be published and can be consulted

Access criteria: An Open Access journal will be searched so that the information can be consulted

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Mar 2027, 0 months later.

Of 102 non-industry observational studies under Hepatitis C, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 0 months is below that.

Counting every sponsor, half of 138 studies reached it within 33 months; a quarter within 18 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Nov 2022 → Mar 2027, primary completion Aug 2023 → Mar 2027 and completion May 2024 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 17, 2022
StartEst.
Mar 15, 2027was Nov 2022
Primary completionEst.
Mar 15, 2027was Aug 2023
CompletionEst.
May 2027was May 2024
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Not yet recruiting
changed Nov 6, 2026
Start date
Nov 15, 2022→Mar 15, 2027
Nov 6, 2026
Primary completion
Aug 15, 2023→Mar 15, 2027
Nov 6, 2026
Study completion
May 15, 2024→May 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Status unknown→Not yet recruiting
    Start date Nov 15, 2022→Mar 15, 2027
    Primary completion Aug 15, 2023→Mar 15, 2027
    Study completion May 15, 2024→May 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05503979
Collaborators
Gilead Sciences
Responsible party
Graciela Elia Castro Narro (Principal Investigator, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran) — Principal investigator
First posted
Aug 17, 2022
Start date
Mar 15, 2027 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Graciela Castro-Narro, MD
Contact
gracastron@yahoo.com
+52 55 5405 3670
Valeria Cortés-Mollinedo, MD
Contact
vale.crts.mllnd@gmail.com
+52 27 1100 7484
Graciela Castro-Narro, MD
principal investigator · INCMNSZ

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion